Background: Vascular anomalies are a heterogeneous group of disorders seen in children and adults. A standard nomenclature for classification has been offered by the International Society for the Study of Vascular Anomalies. Its application is important for communication among the multiple specialties involved in the care of patients and for planning treatment, as well as for research and billing. We hypothesized that terminology still is not uniformly applied, and that this could have an impact on treatment.
INTRODUCTION
Vascular anomalies are a heterogeneous group of disorders that are common in both children and adults. 1 proposed by Mulliken and Glowacki in 1982 . 3 This most recent classification (Table 1) classification is widely accepted, our anecdotal experience suggested that its terminology still is not uniformly applied. This is concerning, since treatment for different types of vascular malformations and for tumors may be very different. We retrospectively searched our institutional vascular anomalies database for patients with nonbrain lesions that had been evaluated clinically, radiographically, and histologically.
Our results confirm that, even at a center with dedicated interest in 
METHODS

Vascular anomalies clinic
In 2008, the University of North Carolina at Chapel Hill (UNC) began to promote a multidisciplinary approach to patients with vascular anomalies with the development of a Vascular Anomalies Clinic. Patients referred to one of the more than 15 participating divisions and departments often are referred internally by the initial contact for sameday visits to at least one of the other divisions, as clinically indicated.
Consults are concentrated among specialists with a specific interest in these problems. Selected cases are reviewed at a monthly clinical management and education conference. 
Vascular anomalies database
Patient selection
Subjects were selected from the above database who had been first explore to what extent these were altered by labeling.
RESULTS
Of the 400 patients recorded in the database who had been seen from 2010 to 2016, 35 patients met eligibility criteria, having been seen by a clinician in one or more divisions and having had both imaging and a biopsy during the same time frame. Patient age at the time of initial evaluation at our center ranged from birth to 64 years (median 6 years); 29 patients (83%) were first seen before the age of 18 years. Twenty-three patients (66%) were female and 12 (34%) were PAHL ET AL.
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male. First clinical evaluations were by otolaryngology (n = 10), pediatric surgery (n = 7), orthopedic surgery (n = 5), pediatric hematology/oncology (n = 4), vascular interventional radiology (n = 4), plastic surgery (n = 2), vascular surgery (n = 1), general surgery (n = 1), and ophthalmology (n = 1).
Location of vascular anomalies was head/neck (n = 14, 40%), axilla (n = 2, 6%), abdomen/pelvis (n = 3, 8%), back (n = 1, 3%), and extremity (n = 15, 43%). Two patients had more than one vascular anomaly, but in both cases all were confined to the head and neck region. None of the patients was diagnosed with a syndrome, possibly reflecting better diagnostic criteria in such individuals, making biopsy for diagnosis unnecessary. Initial imaging evaluations were done using MRI (n = 23, 66%), US (n = 5, 14%), CT (n = 4, 11%), or arteriogram (n = 1, 3%), and two patients (6%) had same-day MRI and US. was a refinement of the original diagnosis (e.g., "vascular malformation" to "VM"). Based on clinic notes, changes seemed to reflect incorporation of pathology results (12 of 25 cases) that had not been available initially, and to a lesser extent of imaging studies that followed the initial clinical encounter. Ten patients were seen on the same day by more than one clinical specialty. Of these 10 individuals, three had both initial and second clinician agree in the diagnosis. This included one patient with an AVM, one patient with an LM, and one patient labeled as a hemangioma (which in actuality was a VM).
Pathology in most cases was based on hematoxylin-eosin staining without use of immune-histochemical stains. Pathology reports diagnosed AVM more frequently than did the other services (n = 9, 25%). Of the nine patients diagnosed with AVM by pathology, five did not have physical examination findings that supported an AVM diagnosis (i.e. no thrill or bruit) and/or imaging studies were not suggestive of a high flow lesion. In four of nine lesions that pathology reports labeled as AVMs, initial clinical or imaging documentation was not sufficient for us to be sure of that diagnosis. LM was the next most common pathologic diagnosis (n = 6, 17%); of these six patients, two had an agreement in diagnosis between all disciplines. Of the remaining four patients diagnosed with LM by pathology, three were labeled as "lymphangioma"
and one as "lymphovascular malformation" by either initial clinician or radiologist using non-ISSVA classification. In five cases (14%), the final report was "vascular malformation," with no further specification. For 23 of the 35 patients, the only available pathology report was following sclerotherapy, embolization, and/or sirolimus, which may have affected the pathology findings and diagnosis.
Imaging diagnosis differed from pathologic diagnosis in 26 of the patients (74%), from initial clinical diagnosis in 22 (63%) and from final clinical diagnosis in 26 (74%). The most common imaging diagnosis was LM (n = 7, 20%), VLM (n = 6, 17%), and hemangioma (n = 5, 14%). In the group of five patients diagnosed with hemangioma by imaging report, two also carried this diagnosis according to clinical report, and none by pathology report. Four of the five ultimately were clinically classified as VM or VLM (with three treated with resection alone, two with sclerotherapy, and one with resection alone), and one as an AVM treated with resection alone. Ten of the 35 patients (29%) had more than one imaging evaluation during the study interval. Of these 10 patients, eight patients (80%) had a change in their imaging diagnosis over time, with different radiologists reading these images. These changing diagnoses were either from a general diagnosis in the first image changed to a more specific diagnosis (i.e., vascular malformation to VLM), from hemangioma to a specific vascular malformation, or even from one type of vascular malformation to another.
Referral information from community healthcare providers was available for only 18 of the 35 patients (51%). The most common referral diagnoses were "soft tissue mass" and/or symptoms related to the mass such as "pain" or "swelling" (n = 14, 78%). Of the other four patients, three were referred with a diagnosis of "hemangioma," and of these one was later determined to have a VM or VLM, one a VM, and the other one an AVM. The remaining patient was referred with a diagnosis of "vascular malformation," which was thought to be correct and with a final diagnosis of VM. Referrals were to a surgical specialty in 10 of 18 cases, eight with a diagnosis of "soft tissue mass" or symptoms related to a mass; two patients were referred to surgery with a referral diagnosis of "hemangioma." Referrals were to VIR in four of 18 cases, for diagnoses of "hemangioma" (n = 1) or "mass" not otherwise specified (n = 3). Two of 18 cases were referred to PHO for evaluation of a correctly labeled "vascular malformation" and a "mass," not otherwise specified. One patient was referred to ophthalmology for proptosis and found to have a retro-orbital hemangioma, and the other to otolaryngology for a mass.
DISCUSSION
Our results confirm that even at a center with a cohort of individuals and disciplines with an interest in vascular anomalies, there often is a lack of concordance about what to call these lesions. Agreement at the time of initial evaluation to our institution-by clinician, radiologist, and pathologist-was noted in only 9% of patients. Even among clinicians from different disciplines, there were differences in how anomalies were labeled at the time of first visit to each. However, these differences usually were clinically insignificant, reflecting how specific the diagnosis was (e.g., "vascular malformation" without a commitment to VM or LM). Clinicians frequently changed their initial diagnosis over time to reflect input from other clinicians and newly available radiology and especially pathology reports.
It is likely that these differences in part reflect a lack of familiarity with or a resistance to adopting ISSVA terminology by many disciplines and practitioners within disciplines who are involved with care It was reassuring that, apart from requiring redirection of patients to different clinicians in our vascular anomalies clinic, we did not see a major impact on treatment decisions. We agree with the prior report 4 that "although a vascular anomaly may be mislabeled, the physician could still understand…the treatment approach." However, our numbers are small and we may be underestimating the impact of imprecise labeling on treatment. It is of note that we more recently saw a child who had been evaluated at a community hospital where biopsy and MRI were said to show a hemangioma. The child was unsuccessfully treated with propranolol. She then was referred to pediatric surgery at our institution that recognized the lesion as a vascular malformation and referred her to pediatric hematology oncology and vascular interventional radiology. Although mislabeling can result in mismanagement, the risk of that is probably low given that treatment is usually deferred to tertiary care centers.
The ISSVA terminology is based on objective clinical, 1 imaging, [6] [7] [8] and pathologic criteria 9, 10 In instances in which a diagnosis cannot be made by history or physical examination, pathology should be able to distinguish glucose transporter type 1 positive IHs from congenital hemangiomas. 9 Other special stains help define vascular malformations, such as CD31 for endothelial cells, prospero-related homeobox (Prox-1), podoplanin or D2-40, and lymphatic vessel endothelial hyaluron receptor 1 for lymphatic endothelium, and CD61, which stains platelets trapped in Kaposiform hemangioendotheliomas. 10, 11 Our experience enforces the need for these diagnostic criteria to have wider dissemination.
This report has several limitations. We used ICD-9 codes to identify potential patients for this study; therefore, we may have missed subjects due to miscoding of diagnoses. We did include a comprehensive list of ICD-9 codes, including both broad and specific diagnoses, in order to minimize missed patients. This study does not reflect comfort with labeling the majority of hemangiomas. These usually do not require imaging or pathology evaluation, and therefore were not a part of this series. Dermatologists at our institution, who have had a longstanding leading role in managing our vascular tumors, and whose medical societies have adopted consensus statements, 12 fewer patients, due to referrals that usually are anatomically driven.
As we expand our multidisciplinary approach and draw in more divisions to see or hear about each patient, we can anticipate improved concordance. Although we did not see major effects on treatment decisions, this is of more than academic interest and has implications for educating referring physicians and families, for research, and possibly for billing and insurance. Families and practitioners who understand a lesion to be a "hemangioma" will have different expectations than they would have if the lesion is thought to be a vascular malformation. As our understanding of the biology and genetics of vascular malformations and tumors continues to grow, 13 it is likely that it will become more essential to accurately label anomalies in order to provide the best and most targeted therapy.
We conclude that an understanding of vascular anomalies as tumors or malformations is not uniform in the community and even in a center with an interest in managing these disorders. Ongoing education will be needed to promote consensus terminology.
